23 April 2024
23 April 2024
At the Swiss Biotech Day conference, experts discussed how the development of antibody drug conjugates (ADCs) may evolve in the near future.
Based on positive outcomes from the Phase III REVISIT and ASSEMBLE trials, the EC adopted its latest decision.
Skyhawk is eligible to receive up to $1.8bn in payments tied to meeting development, regulatory, and commercial milestones.
The deal value could surpass $1bn with Ochre Bio eligible for up to $35m in upfront and near-term milestone payments.
Chiesi also purchased carbon credits to compensate for the emissions for its entire UK portfolio of respiratory medicines.
The niclosamide-based candidate has been repurposed as a cancer treatment by Hyundai and CNPharm after being originally developed for Covid-19.
Based on the safety and efficacy results of a trial involving 77 evaluable patients, the FDA granted approval.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
